Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

ProQR Therapeutics N.V.’s PRQR share price has dipped by 5.52%, which has investors questioning if this is right time to buy.

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

One such example is Novo Nordisk (NYSE: NVO), the Denmark-based pharmaceutical leader whose shares are exchanging hands for ...

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sarat Sethi says Zoetis stock is a better pick than Elanco for 2025. He explained his view in a recent interview with CNBC.

Without a carve-out for tariff exceptions for pharmaceuticals, prices will skyrocket for US patients, experts warn.

Wall Street’s Evan David Seigerman stirred the pot by slashing his price target on Eli Lilly stock—but not his enthusiasm.

We recently published a list of 10 Best Stocks That Will Always Grow. In this article, we are going to take a look at where ...

Shares in pharmaceuticals firm Eli Lilly (LLY) rose today after it said it was suing companies ripping off its weight-loss ...

Rather counterintuitively, following some promising news about a pipeline drug, one analyst tracking Eli Lilly (NYSE: LLY) ...

Eli Lilly ( LLY 3.84%) and Novo Nordisk ( NVO 2.01%) were early leaders in the development of GLP-1 agonists, and dominate the market. Research from MarketsandMarkets suggests that annual global sales ...